Dashboard
1
With a growth in Net Profit of 101.41%, the company declared Very Positive results in Mar 25
- The company has declared positive results for the last 10 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 770.67 MM
- ROCE(HY) Highest at 13.44%
- RAW MATERIAL COST(Y) Fallen by -4.07% (YoY)
2
With ROE of 12.41%, it has a fair valuation with a 5.76 Price to Book Value
3
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 37,211 Million (Large Cap)
46.00
NA
0.20%
-0.29
13.71%
6.31
Revenue and Profits:
Net Sales:
474 Million
(Quarterly Results - Sep 2025)
Net Profit:
204 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
118.52%
0%
118.52%
6 Months
170.94%
0%
170.94%
1 Year
175.89%
0%
175.89%
2 Years
254.99%
0%
254.99%
3 Years
292.08%
0%
292.08%
4 Years
183.66%
0%
183.66%
5 Years
0%
0%
0.0%
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.98%
EBIT Growth (5y)
4.39%
EBIT to Interest (avg)
22.12
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.22
Tax Ratio
4.65%
Dividend Payout Ratio
10.77%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.47%
ROE (avg)
3.89%
Valuation key factors
Factor
Value
P/E Ratio
46
Industry P/E
Price to Book Value
5.76
EV to EBIT
142.65
EV to EBITDA
89.73
EV to Capital Employed
9.77
EV to Sales
24.60
PEG Ratio
NA
Dividend Yield
0.23%
ROCE (Latest)
6.85%
ROE (Latest)
12.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
474.00
342.80
38.27%
Operating Profit (PBDIT) excl Other Income
211.20
115.30
83.17%
Interest
0.00
0.30
-100.00%
Exceptional Items
9.50
4.30
120.93%
Consolidate Net Profit
203.90
98.40
107.22%
Operating Profit Margin (Excl OI)
445.60%
244.50%
20.11%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 38.27% vs 35.60% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 107.22% vs 49.77% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,190.20
1,010.80
17.75%
Operating Profit (PBDIT) excl Other Income
334.50
287.30
16.43%
Interest
1.40
1.60
-12.50%
Exceptional Items
28.90
19.40
48.97%
Consolidate Net Profit
691.40
283.40
143.97%
Operating Profit Margin (Excl OI)
173.60%
189.20%
-1.56%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.75% vs 23.37% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 143.97% vs 524.23% in Dec 2023
About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






